Effects of coadministration of low dose cannabinoid type 2 receptor agonist and morphine on vanilloid receptor 1 expression in a rat model of cancer pain

Zhang,Mingyue; Chi,Meng; Zou,Huichao; Tian,Songyu; Zhang,Zhaodi; Wang,Guonian

doi:10.3892/mmr.2017.7479

Effects of coadministration of low dose cannabinoid type 2 receptor agonist and morphine on vanilloid receptor 1 expression in a rat model of cancer pain

Authors:
- Mingyue Zhang
- Meng Chi
- Huichao Zou
- Songyu Tian
- Zhaodi Zhang
- Guonian Wang
View Affiliations

Affiliations: Department of Anesthesiology, Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China, Department of Pain, Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China, Department of Gynecology, Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China
Published online on: September 13, 2017 https://doi.org/10.3892/mmr.2017.7479
Pages: 7025-7031

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Morphine is widely used as an analgesic to treat moderate to severe pain, but chronic morphine use is associated with development of tolerance and dependence, which limits its analgesic efficacy. Our previous research has showed that nonanalgetic dose of a cannabinoid type 2 (CB2) receptor agonist reduced morphine tolerance in cancer pain. A previous study showed the colocalization of CB2 and transient receptor potential vanilloid 1 (TRPV1) in human and rat dorsal root ganglia (DRG) sensory neurons. Whether coadministration of a CB2 receptor agonist and morphine could reduce TRPV1 expression in morphine‑induced antinociception and tolerance in cancer pain is unclear. Therefore, we investigated the effects of coadministration of a CB2 receptor agonist AM1241 and morphine on TRPV1 expression and tolerance in cancer pain. Coadministration of AM1241 and morphine for 8 days significantly reduced morphine tolerance, as assessed by measuring paw withdrawal latency to a radiant heat stimulation, in Walker 256 tumor‑bearing rats. Repeated morphine treatment for a period of 8 days induced upregulation of the TRPV1 protein expression levels in the DRG in the tumor‑bearing rats, although no change in mRNA expression. Pretreatment with AM1241 reduced this morphine‑induced upregulation of TRPV1 and the effect was reversed by the CB2 receptor antagonist AM630. Our findings suggest that coadministration of a CB2 receptor agonist AM1241 and morphine reduced morphine tolerance possibly through regulation of TRPV1 protein expression in the DRG in cancer pain.

View Figures

View References

1	Mercadante S: The use of opioids for treatment of cancer pain. Expert Opin Pharmacother. 16:389–394. 2015.PubMed/NCBI
2	Watkins LR, Hutchinson MR, Johnston IN and Maier SF: Glia: Novel counter-regulators of opioid analgesia. Trends Neurosci. 28:661–669. 2005. View Article : Google Scholar : PubMed/NCBI
3	Nagi K and Piñeyro G: Regulation of opioid receptor signalling: Implications for the development of analgesic tolerance. Mol Brain. 4:252011. View Article : Google Scholar : PubMed/NCBI
4	Tumati S, Largent-Milnes TM, Keresztes A, Ren J, Roeske WR, Vanderah TW and Varga EV: Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist. J Neuroimmunol. 244:23–31. 2012. View Article : Google Scholar : PubMed/NCBI
5	Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Böhme GA, Imperato A, Pedrazzini T, Roques BP, et al: Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science. 283:401–404. 1999. View Article : Google Scholar : PubMed/NCBI
6	De Vry J, Jentzsch KR, Kuhl E and Eckel G: Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development. Behav Pharmacol. 15:1–12. 2004. View Article : Google Scholar : PubMed/NCBI
7	Pertwee RG: Cannabinoid receptors and pain. Prog Neurobiol. 63:569–611. 2001. View Article : Google Scholar : PubMed/NCBI
8	Beltramo M, Bernardini N, Bertorelli R, Campanella M, Nicolussi E, Fredduzzi S and Reggiani A: CB2 receptor-mediated antihyperalgesia: Possible direct involvement of neural mechanisms. Eur J Neurosci. 23:1530–1538. 2006. View Article : Google Scholar : PubMed/NCBI
9	Romero-Sandoval A, Nutile-McMenemy N and DeLeo JA: Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury. Anesthesiology. 108:722–734. 2008. View Article : Google Scholar : PubMed/NCBI
10	Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, Meozzi PA, Myers L, Mora Z, Tagliaferro P, Gardner E, et al: Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci. 1074:514–536. 2006. View Article : Google Scholar : PubMed/NCBI
11	Onaivi ES, Ishiguro H, Gong JP, Patel S, Meozzi PA, Myers L, Perchuk A, Mora Z, Tagliaferro PA, Gardner E, et al: Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann N Acad Sci. 1139:434–449. 2008. View Article : Google Scholar
12	Anand U, Otto WR, Sanchez-Herrera D, Facer P, Yiangou Y, Korchev Y, Birch R, Benham C, Bountra C, Chessell IP and Anand P: Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons. Pain. 138:667–680. 2008. View Article : Google Scholar : PubMed/NCBI
13	Lim G, Wang S and Mao J: Central glucocorticoid receptors modulate the expression of spinal cannabinoid receptors induced by chronic morphine exposure. Brain Res. 1059:20–27. 2005. View Article : Google Scholar : PubMed/NCBI
14	Desroches J, Bouchard JF, Gendron L and Beaulieu P: Involvement of cannabinoid receptors in peripheral and spinal morphine analgesia. Neuroscience. 261:23–42. 2014. View Article : Google Scholar : PubMed/NCBI
15	Cichewicz DL and Welch SP: Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther. 305:812–817. 2003. View Article : Google Scholar : PubMed/NCBI
16	Cichewicz DL: Synergistic interactions between cannabinoid and opioid analgesics. Life Sci. 74:1317–1324. 2004. View Article : Google Scholar : PubMed/NCBI
17	Bushlin I, Rozenfeld R and Devi LA: Cannabinoid-opioid interactions during neuropathic pain and analgesia. Curr Opin Pharmacol. 10:80–86. 2010. View Article : Google Scholar : PubMed/NCBI
18	Zhang M, Wang K, Ma M, Tian S, Wei N and Wang G: Low-dose cannabinoid type 2 receptor agonist attenuates tolerance to repeated morphine administration via regulating µ-Opioid Receptor expression in Walker 256 tumor-bearing rats. Anesth Analg. 122:1031–1037. 2016. View Article : Google Scholar : PubMed/NCBI
19	Ma W and Quirion R: Inflammatory mediators modulating the transient receptor potential vanilloid 1 receptor: Therapeutic targets to treat inflammatory and neuropathic pain. Expert Opin Ther Targets. 11:307–320. 2007. View Article : Google Scholar : PubMed/NCBI
20	Zhang Z, Wang C, Gu G, Li H, Zhao H, Wang K, Han F and Wang G: The effects of electroacupuncture at the ST36 (Zusanli) acupoint on cancer pain and transient receptor potential vanilloid subfamily 1 expression in Walker 256 tumor-bearing rats. Anesth Analg. 114:879–885. 2012. View Article : Google Scholar : PubMed/NCBI
21	Chen Y, Geis C and Sommer C: Activation of TRPV1 contributes to morphine tolerance: Involvement of the mitogen-activated protein kinase signaling pathway. J Neurosci. 28:5836–5845. 2008. View Article : Google Scholar : PubMed/NCBI
22	Nguyen TL, Nam YS, Lee SY, Kim HC and Jang CG: Effects of capsazepine, a transient receptor potential vanilloid type 1 antagonist, on morphine-induced antinociception, tolerance, and dependence in mice. Br J Anaesth. 105:668–674. 2010. View Article : Google Scholar : PubMed/NCBI
23	Patwardhan AM, Jeske NA, Price TJ, Gamper N, Akopian AN and Hargreaves KM: The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc Natl Acad Sci USA. 103:11393–11398. 2006; View Article : Google Scholar : PubMed/NCBI
24	Devesa I and Ferrer-Montiel A: Neurotrophins, endocannabinoids and thermo-transient receptor potential: A threesome in pain signalling. Eur J Neurosci. 39:353–362. 2014. View Article : Google Scholar : PubMed/NCBI
25	Brigatte P, Sampaio SC, Gutierrez VP, Guerra JL, Sinhorini IL, Curi R and Cury Y: Walker 256 tumor-bearing rats as a model to study cancer pain. J Pain. 8:412–421. 2007. View Article : Google Scholar : PubMed/NCBI
26	Wang ZB, Gan Q, Rupert RL, Zeng YM and Song XJ: Thiamine, pyridoxine, cyanocobalamin and their combination inhibit thermal, but not mechanical hyperalgesia in rats with primary sensory neuron injury. Pain. 114:266–277. 2005. View Article : Google Scholar : PubMed/NCBI
27	Szallasi A, Cortright DN, Blum CA and Eid SR: The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov. 6:357–372. 2007. View Article : Google Scholar : PubMed/NCBI
28	Ossipov MH, Lai J, King T, Vanderah TW and Porreca F: Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. Biopolymers. 80:319–324. 2005. View Article : Google Scholar : PubMed/NCBI
29	Mao J, Price DD and Mayer DJ: Mechanisms of hyperalgesia and opiate tolerance: A current view of their possible interactions. Pain. 62:259–2274. 1995. View Article : Google Scholar : PubMed/NCBI
30	Mayer DJ, Mao J, Holt J and Price DD: Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Proc Natl Acad Sci USA. 96:7731–7736. 1999; View Article : Google Scholar : PubMed/NCBI
31	Endres-Becker J, Heppenstall PA, Mousa SA, Labuz D, Oksche A, Schäfer M, Stein C and Zöllner C: Mu-opioid receptor activation modulates transient receptor potential vanilloid 1 (TRPV1) currents in sensory neurons in a model of inflammatory pain. Mol Pharmacol. 71:12–18. 2007. View Article : Google Scholar : PubMed/NCBI
32	Niiyama Y, Kawamata T, Yamamoto J, Furuse S and Namiki A: SB366791, a TRPV1 antagonist, potentiates analgesic effects of systemic morphine in a murine model of bone cancer pain. Br J Anaesth. 102:251–258. 2009. View Article : Google Scholar : PubMed/NCBI
33	Jeske NA, Patwardhan AM, Gamper N, Price TJ, Akopian AN and Hargreaves KM: Cannabinoid WIN 55,212-2 regulates TRPV1 phosphorylation in sensory neurons. J Biol Chem. 281:32879–32890. 2006. View Article : Google Scholar : PubMed/NCBI
34	Chen Y and Sommer C: The role of mitogen-activated protein kinase (MAPK) in morphine tolerance and dependence. Mol Neurobiol. 40:101–107. 2009. View Article : Google Scholar : PubMed/NCBI
35	Landry RP, Martinez E, DeLeo JA and Romero-Sandoval EA: Spinal cannabinoid receptor type 2 agonist reduces mechanical allodynia and induces mitogen-activated protein kinase phosphatases in a rat model of neuropathic pain. J Pain. 13:836–848. 2012. View Article : Google Scholar : PubMed/NCBI
36	Dhopeshwarkar A and Mackie K: CB2 Cannabinoid receptors as a therapeutic target-what does the future hold? Mol Pharmacol. 86:430–437. 2014. View Article : Google Scholar : PubMed/NCBI
37	Cui Y, Chen Y, Zhi JL, Guo RX, Feng JQ and Chen PX: Activation of p38 mitogen-activated protein kinase in spinal microglia mediates morphine antinociceptive tolerance. Brain Res. 1069:235–243. 2006. View Article : Google Scholar : PubMed/NCBI